en.Wedoany.com Reported - Evogene Ltd. recently announced the completion of a significant milestone in collaboration with Google Cloud, integrating an agentic computing system into its ChemPass AI™ platform. This system is designed to help researchers quickly identify key success requirements at the earliest stages of small molecule development, shortening discovery timelines, improving scalability, and significantly increasing the overall probability of success.

Small molecule development requires identifying candidate molecules that meet complex biological, chemical, clinical, and commercial requirements, as defined by the Target Product Profile (TPP). In traditional approaches, many key requirements are only assessed later in development, and researchers often fail to predict downstream challenges when selecting early candidate molecules, leading to project delays, inefficient allocation of R&D resources, high attrition rates, and increased development risks.

To address these challenges, the enhanced ChemPass AI™ engine leverages Google's Gemini models and the Gemini Enterprise Agent Platform, aiming to achieve earlier and deeper biological TPP analysis. This capability is driven by autonomous AI agent workflows that integrate structural, biological, chemical, and clinical data to independently analyze targets. ChemPass is designed to simultaneously address a large number of requirements during the molecular design and generation process, enabling research teams to prioritize compounds with the highest development and commercial potential from the very beginning of the discovery phase, before committing significant resources.

This milestone was achieved through the ongoing collaboration between Evogene and Google Cloud. Google Cloud's enterprise-grade AI infrastructure and platform provide the foundation for building scalable, next-generation autonomous discovery capabilities.

Boaz Maoz, Managing Director of Google Cloud Israel, stated that Evogene is redefining the life sciences field by leveraging Google Cloud's full AI stack. By using Gemini models and implementing agentic AI, they can accelerate the discovery of new molecules, demonstrating the application of AI in simplifying complex biological and chemical research.

Ofer Haviv, President and CEO of Evogene, noted that this milestone advances the vision of redefining molecular discovery and optimization through AI. Integrating advanced AI agents into ChemPass AI™ enables the generation of richer target profiles earlier, thereby predicting downstream requirements and prioritizing high-potential candidate molecules. The company's goal is to build autonomous computing systems that predict key success requirements at the earliest stages of development, potentially addressing complex protein challenges in the development of new therapies.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com